A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.
نویسندگان
چکیده
We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3-4 weeks, the aim of the current study was to establish the anti-tumour and bone effects of a single administration of doxorubicin/zoledronic acid combination therapy in a bone metastasis model. MDA-MB-231-GFP cells were injected i.c. in 6-week-old nude mice. On day 2, animals received PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 μg/kg s.c.) or doxorubicin followed 24 h later by zoledronic acid. Anti-tumour effects were assessed on days 15/23 by quantification of apoptotic and proliferating cells and changes in expression of genes implicated in apoptosis, proliferation and bone turnover. Bone effects were assessed by μCT analysis, bone histomorphometry and measurement of serum markers. A tumour-free control group was included. Combination treatment reduced bone tumour burden compared to single agent or PBS control and increased levels of tumour cell apoptosis on day 15, but this was no longer detectable on day 23. Animals receiving zoledronic acid had increased bone density, without evidence of tumour-induced lesions. Bone histomorphometry showed that zoledronic acid caused a decrease in osteoblast and osteoclast numbers and an increase in osteoclast size, in both tumour-free and tumour-bearing animals. Our data show that although zoledronic acid modifies the bone microenvironment through effects on both osteoblasts and osteoclasts, this does not result in a significant anti-tumour effect in the absence of doxorubicin.
منابع مشابه
Breast Cancer Metastases to Bone: Role of the Microenvironment
Bone is the preferred site for breast cancer metastasis, which leads to altered mineral metabolism, disruption of bone architecture, and considerable pain burden. Prior to homing to the bone, the primary breast tumour releases soluble factors that lead to the creation of a pre-metastatic niche in the bone, which then serves to attract and maintain invading breast cancer cells. Breast cancer cel...
متن کاملCombination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells
Objective(s): Breast cancer remains a global challenge, and further chemopreventive therapies are still immediately required. Emerging evidence has revealed the potent anti-cancer effects of biguanides, Metformin (MET) and phenformin (PHE). Thus, to explore an efficient chemopreventive strategy for breast cancer, the antiproliferative effects of the combination of MET and PHE against breast can...
متن کاملCancer Therapy: Preclinical Inhibition of Prostate Cancer Osteoblastic Progression with VEGF121/rGel, a Single Agent Targeting Osteoblasts, Osteoclasts, and Tumor Neovasculature
Purpose: A hallmark of prostate cancer (PCa) progression is the development of osteoblastic bone metastases, which respond poorly to available therapies. We previously reported that VEGF121/rGel targets osteoclast precursors and tumor neovasculature.Herewe tested the hypothesis that targetingnontumor cells expressing these receptors can inhibit tumor progression in a clinically relevant model o...
متن کاملBisphosphonates and metastatic bone disease.
Malignant bone disease is a frequent complication of several common solid tumours including breast, lung, prostate and renal cancer. A greater understanding of tropic bone tumour cells, especially the understanding of those properties which lead to their successful growth within the bone microenvironment is the first step to devise innovative approaches. Bone metastases are generally characteri...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of bone oncology
دوره 1 2 شماره
صفحات -
تاریخ انتشار 2012